High‐dose, high‐frequency ustekinumab therapy for patients with severe hidradenitis suppurativa

High‐dose, high‐frequency ustekinumab therapy for patients with severe hidradenitis suppurativa

In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of dermatology (1951) 2022-09, Vol.187 (3), p.417-419
Hauptverfasser: Jiang, Simon W., Kwock, Jeffery T., Liu, Beiyu, Petty, Amy J., Zhao, Aaron T., Green, Cynthia L., Jaleel, Tarannum
Format: Artikel
Sprache:eng
Schlagworte:
Infliximab
Monoclonal antibodies
Patients
Tumor necrosis factor-α
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.21066